Galderma Reaches Agreement to Acquire CollaGenex Pharm...(innovativemedical therapies to the derma...),Health

Date:2/25/2008

innovative medical therapies to the dermatology market. In July 2006, CollaGenex launched Oracea(R), the first FDA-approved systemic product for the treatment of rosacea. Collagenex's professional dermatology sales force also markets Alcortin(R) (1% iodoquinol and 2% hydrocortisone), a prescription topical antifungal steroid combination, and Novacort(R) (2% hydrocortisone acetate and 1% pramoxine HCl), a prescription topical steroid and anesthetic. CollaGenex recently completed a Phase II clinical trial to evaluate COL-118, a topical compound based on the SansRosa(R) technology, for the treatment of redness associated with rosacea and other skin disorders. CollaGenex recently acquired the rights to develop and commercialize becocalcidiol, a patented Vitamin D analogue that is currently in Phase II clinical trials for the topical treatment of mild to moderate psoriasis.

For more information on CollaGenex please visit their Web site at http://www.collagenex.com, which does not form part of this press release.

Important Information about the Tender Offer

This announcement and the description contained herein are not a recommendation, an offer to purchase or a solicitation of an offer to sell securities of CollaGenex. The tender offer described herein has not commenced. At the time the expected tender offer is commenced, Galderma intends to file with the Securities and Exchange Commission a tender offer statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal, and other related documents. Following commencement of the tender offer, CollaGenex will file with the Securities and Exchange Commission a solicitation/recommendation statement on Schedule 14D-9. Shareholders should read the offer to purchase and solicitation/recommendation statement and related exhibits when such documents are filed and become available, as they will contain important informati
'/>"/>

SOURCE Galderma Pharma S.A. Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
2. Spiritual Healer/Psychic-Medium Reaches International Status!
3. EMBL reaches north
4. AK Steel Reaches VEBA Health Care Settlement With Middletown Works Retirees
5. Sun Safety Awareness Reaches New Heights at Plano Hot Air Balloon Festival
6. 40 Days for Life Reaches Halfway Point; Planned Parenthood Now in Crisis Mode
7. Blue Cross of California Reaches Out to Members Impacted by Southern California Fires
8. Free Site Offering Patient-Physician Dialog Reaches Milestone
9. Sharp HealthCare Foundation Reaches $50 Million Goal
10. Nyer Medical Group Reaches Agreement to Acquire Minority Interest in Pharmacy Chain Subsidiary
11. MB Software Corporation Reaches Agreement with Keystone Equity Partners